Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 755–756 | Cite as

ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses

  • George C. Mayne
  • David I. Watson
  • Karen Chiam
  • Damian J. HusseyEmail author
ASO Author Reflections
  • 35 Downloads

Past

Treatment for locally advanced esophageal adenocarcinoma usually involves neoadjuvant chemotherapy or chemoradiotherapy, followed by surgical resection. Neoadjuvant treatment improves survival rates, but only 30% of patients have complete pathological response, and survival is improved in only 10–15% of patients compared with surgery alone.1 Furthermore, neoadjuvant chemoradiotherapy can increase morbidity and make some patients unfit for surgery. Whilst some patients do benefit from neoadjuvant therapies, many more might actually be subjected to treatment toxicity and have their surgery delayed for no survival advantage.

As clinicopathological factors are not sufficiently accurate to predict which patients will actually benefit versus not benefit from neoadjuvant therapy, it has been suggested that future research should focus on molecular classifiers.2MicroRNAs (miRNAs) are small noncoding RNAs that are known to be important in directing the behavior of cancers, including...

Notes

Disclosure

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.CrossRefGoogle Scholar
  2. 2.
    Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience. Cancer 2017;123(21):4106–13.CrossRefGoogle Scholar
  3. 3.
    Peng R. The reproducibility crisis in science: a statistical counterattack. Significance. 2015;12(3):30–2.CrossRefGoogle Scholar
  4. 4.
    Chiam K, Mayne GC, Watson DI, et al. Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing. Ann Surg Oncol. 2018;25(9):2731–8.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • George C. Mayne
    • 1
    • 2
  • David I. Watson
    • 1
    • 2
  • Karen Chiam
    • 1
    • 3
  • Damian J. Hussey
    • 1
    • 2
    Email author
  1. 1.Discipline of Surgery, College of Medicine and Public HealthFlinders UniversityAdelaideAustralia
  2. 2.Flinders Centre for Innovation in Cancer, College of Medicine and Public HealthFlinders UniversityAdelaideAustralia
  3. 3.Cancer Research DivisionCancer Council New South WalesSydneyAustralia

Personalised recommendations